LP227842-4
BTK gene targeted mutation analysis
Active
Description
Bruton's tyrosine kinase (BTK) plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies. BTK was initially shown to be defective in the primary immunodeficiency X-linked agammaglobulinemia (XLA) and B cell development and the function of mature B cells. The orally administered irreversible BTK inhibitor ibrutinib is associated with high response rates in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). PMID: 29455639 Source: NCBI PubMed
Basic Part Properties
- Part Name
- BTK gene targeted mutation analysis
- Part Display Name
- BTK gene targeted mutation analysis
- Part Type
- Component (Describes the core component or analyte measured)
- Created On
- 2016-09-13
- Construct for LOINC Short Name
- BTK gene targeted mutation analysis
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=LP227842-4
LOINC Copyright
Copyright © 2025 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://